ES2154806T3 - Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles. - Google Patents

Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles.

Info

Publication number
ES2154806T3
ES2154806T3 ES96904552T ES96904552T ES2154806T3 ES 2154806 T3 ES2154806 T3 ES 2154806T3 ES 96904552 T ES96904552 T ES 96904552T ES 96904552 T ES96904552 T ES 96904552T ES 2154806 T3 ES2154806 T3 ES 2154806T3
Authority
ES
Spain
Prior art keywords
digerable
nanoparticles
dispersions
formulations
oils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96904552T
Other languages
English (en)
Inventor
W Mark Eickhoff
Karl R Mueller
David A Engers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/384,057 external-priority patent/US5571536A/en
Priority claimed from US08/388,088 external-priority patent/US5560931A/en
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Application granted granted Critical
Publication of ES2154806T3 publication Critical patent/ES2154806T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Edible Oils And Fats (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LOS FARMACOS EN FORMA DE NANOPARTICULAS CRISTALINAS FORMULADOS EN UNA FASE ACUOSA EMULSIFICADA EN ACEITE, SE PUEDEN OBTENER CON UN TAMAÑO INFERIOR A 1.000 NM Y FAVORECER ASI UN AUMENTO DE LA BIODISPONIBILIDAD Y DE LA ABSORCION LINFATICA TRAS LA ADMINISTRACION ORAL.
ES96904552T 1995-02-06 1996-01-31 Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles. Expired - Lifetime ES2154806T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/384,057 US5571536A (en) 1995-02-06 1995-02-06 Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US08/388,088 US5560931A (en) 1995-02-14 1995-02-14 Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids

Publications (1)

Publication Number Publication Date
ES2154806T3 true ES2154806T3 (es) 2001-04-16

Family

ID=27010448

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96904552T Expired - Lifetime ES2154806T3 (es) 1995-02-06 1996-01-31 Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles.

Country Status (11)

Country Link
EP (1) EP0808154B1 (es)
JP (1) JPH10513200A (es)
AT (1) ATE198148T1 (es)
AU (1) AU4862796A (es)
CA (1) CA2207304A1 (es)
DE (1) DE69611287T2 (es)
DK (1) DK0808154T3 (es)
ES (1) ES2154806T3 (es)
GR (1) GR3035613T3 (es)
PT (1) PT808154E (es)
WO (1) WO1996024332A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1999049846A2 (en) 1998-03-30 1999-10-07 Rtp Pharma Inc. Compositions containing microparticles of water-insoluble substances and method for their preparation
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CN102316726A (zh) * 2008-12-18 2012-01-11 巴斯夫欧洲公司 包含农药颗粒和两亲物的水分散体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
DE3623376A1 (de) * 1986-07-11 1988-01-21 Behringwerke Ag Pharmazeutische formulierung und verfahren zu deren herstellung
IL88076A (en) * 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions

Also Published As

Publication number Publication date
WO1996024332A1 (en) 1996-08-15
PT808154E (pt) 2001-06-29
DE69611287D1 (de) 2001-01-25
EP0808154A1 (en) 1997-11-26
CA2207304A1 (en) 1996-08-15
ATE198148T1 (de) 2001-01-15
DK0808154T3 (da) 2001-04-30
DE69611287T2 (de) 2001-08-09
JPH10513200A (ja) 1998-12-15
AU4862796A (en) 1996-08-27
EP0808154B1 (en) 2000-12-20
GR3035613T3 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
ES2154806T3 (es) Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles.
EP1032363B1 (en) Conjugated linoleic acid delivery system in cosmetic preparations
DE3579069D1 (de) Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung.
TR200504156T2 (tr) Psikiyatrik ve nörolojik bozukluklar için yüksek ölçüde saflaştırılmış etil EPA ve diğer EPA türevleri.
DK1429731T3 (da) Nanopartikelformuleringer indeholdende insulin
DE69809074D1 (de) Herstellung von arzneimitteln
ATE236627T1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
EP0406162A3 (en) Process for the preparation of a nanoemulsion of oilparticles in an aqueous phase
DE69534306D1 (de) Arzneimittel
ATE172111T1 (de) Arzneizusammensetzungen enthaltend nanokapseln
WO2008047680A1 (fr) Préparation externe pour la peau
EP1072246A3 (de) Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
ATE415410T1 (de) Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten
BR0009340A (pt) Composição adequada para uso na pele ou no cabelo, produto para aplicação na pele ou no cabelo, método para preparar uma composição adequada para aplicação na pele ou no cabelo, e, uso de uma composição
JP3867123B2 (ja) アゼライン酸を含む組成物
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
ATE101036T1 (de) Aktivitaetspotenziator gegen krebs.
KR910005841A (ko) 피부 미소순환에 작용하는 약리적 조성물
ID15895A (id) Formulasi untuk menurunkan kolesterol darah dan penyerapan lemak berbagai fungsi
TR200002078T2 (tr) Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar.
DE60106406D1 (de) Zubereitungen zur anwendung als penetrationförderer in transdermalen arzneimitteln die hoch-lipophile wirkstoffe enthalten
ATE131031T1 (de) Zubereitung zur topischen anwendung.
GEP20033046B (en) Parenteral Cisplatin Emulsion
ATE355825T1 (de) Amphotericin b enthaltende strukturierte emulsion

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 808154

Country of ref document: ES